Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Peri Inj. Compared With RPN301
NCT ID: NCT05337228
Last Updated: 2023-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
59 participants
INTERVENTIONAL
2022-08-09
2023-02-24
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Trial to Evaluate the Safety and Efficacy of IN-C006 Inj. Compared With RCN301
NCT05299099
Immunonutrition Versus Standard Enteral Nutrition Before Major Surgery
NCT00512213
The Impact of Low Calorie and Low Nitrogen Parenteral Nutrition Support on the Clinical Outcome of Postoperative Patients
NCT00247338
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
NCT06625931
Efficacy & Safety of SmofKabiven Emulsion for Infusion vs Hospital Compounded "All in One" for Parenteral Nutrition
NCT03792100
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IN-C006 Peri inj.
IN-C006 Peri inj. 1904 mL
IN-C006 Peri inj.
IN-C006 peri inj. will be injected continuously for 3 days.
RPN301
RPN301 2020 mL
RPN301
RPN301 will be injected continuously for 3 days.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
IN-C006 Peri inj.
IN-C006 peri inj. will be injected continuously for 3 days.
RPN301
RPN301 will be injected continuously for 3 days.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Requiring over 3 days of parenteral nutrition via a peripheral vein after an operation
* BMI 16 \~ 30 kg/㎡
Exclusion Criteria
* Severe dyslipidemia
* Uncontrolled diabetes
* Clinically significant liver disease
* Clinically significant kidney disease
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HK inno.N Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Do Joong PARK
Role: STUDY_CHAIR
Seoul National Univerity Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Seoul National University Hospital
Seoul, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IN_PPN_301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.